Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain bleed patients: could the right IV fluid save more lives?

NCT ID NCT04043598

Disease control Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 320 adults who had a brain bleed (subarachnoid hemorrhage) to see if the type of IV fluid they receive affects their recovery. The goal is to find out if a fluid with a specific salt content can reduce dangerous complications like blood vessel spasms and brain swelling. Participants are randomly assigned to one of two common IV fluids, and researchers track their outcomes in the hospital.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All adult patients suffering from non-traumatic subarachnoid haemorrhage. Exclusion Criteria: * Patients with major intra-cranial trauma * Diagnosis of an AV-malformation as the source of subarachnoid hemorrhage on the primary CT/MRI or angiography * More than 24 hours after diagnosis of subarachnoid haemorrhage as diagnosed by cerebral imaging (CT scan or MRI) * Patients with clear limitation to therapy at hospital admission (eg ICU admission for evaluation of organ donation) * Declining of informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critical illness are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critical illness Infusion fluid Sodium disorder Subarachnoid hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Intensive Care Medicine

    RECRUITING

    Geneva, 1205, Switzerland

  • Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland

    RECRUITING

    Bern, 3010, Switzerland

  • Department of perioperative Intensive Care Medicine

    RECRUITING

    Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.